Inaqovi

Decitabine, the active ingredient in Inaqovi, is a DNA methyltransferase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of myelodysplastic syndromes and acute myeloid leukemia in adult patients. GNH USA supplies Inaqovi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Inaqovi is used in hematologic malignancies that involve abnormal DNA methylation. Myelodysplastic syndromes (MDS): improves blood cell production and may delay progression to acute leukemia. Acute myeloid leukemia (AML): provides disease control for patients unsuitable for intensive chemotherapy.

Inaqovi may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Fatigue or weakness - Low blood counts (anemia, neutropenia, thrombocytopenia) - Diarrhea or constipation - Fever or chills - Elevated liver enzymes

Serious or Rare Side Effects: - Severe infections due to neutropenia - Bleeding complications from thrombocytopenia - Pulmonary toxicity (e.g., interstitial pneumonitis) - Cardiac arrhythmias or myocarditis - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Renal impairment or failure

Before initiating therapy, clinicians should evaluate baseline organ function and monitor patients regularly. Baseline blood counts: obtain complete blood count with differential. Renal function: assess serum creatinine and calculate eGFR. Hepatic function: check liver enzymes and bilirubin levels. Infection risk: monitor for signs of infection and manage promptly. Pregnancy and lactation: avoid use unless benefits outweigh risks; discuss contraception. Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Inaqovi can interact with other medicines that affect blood cell production or metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) that may reduce exposure to cedazuridine. - Concurrent use of other hypomethylating agents or cytotoxic chemotherapy that markedly increase myelosuppression. - Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, DOACs): monitor coagulation parameters. - Drugs that prolong QT interval: observe cardiac rhythm. - NSAIDs or other agents that can cause gastrointestinal bleeding: assess bleeding risk.